## CITATION REPORT List of articles citing

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kongs Omicron BA.2 wave: an observational study

DOI: 10.1101/2022.05.19.22275291

,,,,

Source: https://exaly.com/paper-pdf/146024625/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	The SARS-CoV-2 main protease (M pro ): Structure, function, and emerging therapies for COVID-19. <i>MedComm</i> , <b>2022</b> , 3,	2.2	4
13	Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.		0
12	Oral antiviral treatments for COVID-19: opportunities and challenges. <i>Pharmacological Reports</i> ,	3.9	4
11	A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2.		
10	Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. <i>International Journal of Infectious Diseases</i> , <b>2022</b> , 122, 599-601	10.5	1
9	Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study.		6
8	Determining population-level allocation strategies for COVID-19 treatments in the United States using a quantitative framework, a case study using nirmatrelvir/ritonavir.		
7	Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.		3
6	Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir.		1
5	Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19. 2022,		2
4	New Therapeutic Options in Mild Moderate COVID-19 Outpatients. <b>2022</b> , 10, 2131		1
3	Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.		О
2	Effectiveness of Paxlovid - a review.		0
1	REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUBEC, CANADA.		0